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ABSTRACT 
The autonomic nervous system (ANS) has been implicated in numerous 
atherosclerosis-induced cardiovascular disease, such as myocardial infarction 
and stroke. Although evidence suggests a relationship between autonomic 
dysfunction and atherosclerotic disease, the mediating mechanisms are still 
elusive. Considering the inflammatory pathophysiology of atherogenesis, we 
have investigated the role of nerve-driven immunity in this relationship, with 
focus on the alpha 7 nicotinic acetylcholine receptor (α7nAChR).  
The link between ANS dysfunction, inflammation and prevalent disease 
was assessed in male subjects. The athero-protective effects of sympathetic 
inhibition and α7nAChR-signaling were investigated in atherosclerosis-prone 
mice, by β1-blocker treatment with metoprolol, α7nAChR-stimulation with 
AZ6983, or by hematopoietic ablation of α7nAChR.  
Our original contribution to knowledge includes data showing that 
inflammation could be a mediator in the association between dysfunction in 
the ANS and carotid atherosclerosis in humans, and that the athero-protective 
effects of metoprolol may include suppression of atherogenic cytokines. 
Further, for the first time, we show that α7nAChR-deficiency was associated 
with increased atherosclerosis, whereas α7nAChR-stimulation with AZ6983 
reduced atherosclerosis and modulated both innate and adaptive immune 
responses. The α7nAChR was identified on immune cells in human carotid 
plaques, and stimulation by AZ6983 inhibited cytokine production in human 
blood, suggesting athero-protective effects of AZ6983 also in humans.   
Taken together, our findings suggest that the balance between the 
sympathetic and parasympathetic branch of the ANS have an impact on 
atherosclerosis, and that inflammation is mediator. We propose that the 
α7nAChR is an interesting pharmacological target in this pathway.    
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 SAMMANFATTNING PÅ SVENSKA 
Åderförfettning är en inflammatorisk sjukdom och den främsta orsaken 
till hjärt- och kärlsjukdomar. Åderförfettning startar ofta i tidig ålder och kan 
med tiden utvecklas till åderförfettningsplack som i allvarliga fall brister och 
leder till fatala komplikationer så som hjärtinfarkt och stroke. Rökning, höga 
kolesterolvärden, diabetes och högt blodtryck ökar risken för hjärt-
kärlsjukdom, men studier visar även att förändringar i det autonoma 
nervsystemet kan vara en riskfaktor. Syftet med den här avhandlingen var att 
studera det autonoma nervsystemets roll i åderförfettning, med fokus på om 
inflammation kan vara en bidragande faktor. 
Det autonoma nervsystemet reglerar kroppens icke viljestyrda funktioner 
så som andning, hjärtats rytm, kroppstemperatur, och delas in i det 
sympatiska nervsystemet, som är aktivt vid stress och kampsituationer, och 
det parasympatiska nervsystemet, som är aktivt vid vila. Tidigare 
humanstudier visar att det kan finnas en länk mellan dysfunktion i det 
autonoma nervsystemet och åderförfettning. Vi fann att orsaken kan vara att 
försämrad funktion av det autonoma nervsystemet leder till inflammation, 
som slutligen orsakar åderförfettning. Vi fann även att blockering av det 
sympatiska nervsystemet, genom metoprololbehandling, minskade både 
åderförfettning och nivå av cirkulerande inflammatoriska proteiner i möss. 
Tillsammans indikerar resultaten att inflammation påverkas av balansen 
mellan det sympatiska och det parasympatiska nervsystemet, som i sin tur har 
effekt på utvecklingen av åderförfettning.  
Djurstudier har vid andra inflammatoriska sjukdomar visat på en 
skyddande effekt av att stimulera det parasympatiska nervsystemet, där alfa 7 
nikotinacetylkolinreceptorn har visat sig vara en viktig del av mekanismen. 
Vi visar här att receptorn även fyller en funktion i åderförfettning. Tar man 
bort receptorn från benmärgsceller i möss så förvärras åderförfettningen, men 
stimulerar man receptorn med en agonist så sker förändringar i 
immunsystemet och sjukdomen minskar. Vi identifierade även receptorn på 
immunceller i åderförfettningsplack från människa, samt visade att 
behandling av humana blodceller med agonisten minskade produktionen av 
inflammatoriska proteiner. Detta visar att receptorn kan fylla en viktig 
funktion för åderförfettning även i människa. 
Sammanfattningsvis antyder resultaten att balansen mellan det sympatiska 
och det parasympatiska nervsystemet har en påverkan på åderförfettning och 
att inflammation är en viktig mediator. Vi föreslår att alpha 7 
nikotinacetylkolinreceptorn kan fylla en viktig funktion i 
åderförfettningsprocessen.
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1 INTRODUCTION 
1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is the leading cause of death in the world, 
accounting for 32% of global mortality in 2012 (1). Although existing 
treatment methods are becoming more effective, the prevalence is still 
increasing (1). CVD encompasses a range of diseases that involve the heart 
and blood vessels. Many of these conditions, including stroke, peripheral 
artery disease and coronary artery disease (CAD), result from the formation 
of atherosclerotic lesions in the vessels. Together, stroke and CAD accounted 
for 78% of all cardiovascular deaths in 2008 (2), while non-fatal events can 
cause major sequelae, such as paralysis. The severe complications of 
atherosclerosis call for extensive research on the underlying risk factors, and 
on the mechanisms involved, for future prevention and pharmacological 
therapies.   
1.2 Atherosclerosis 
1.2.1 Overview 
Atherosclerosis is a slowly developing disease that affects large and medium 
sized vessels, and is characterized by thickening of the endothelium-
containing intima, the innermost layer of the arterial wall. Lesions are 
predominantly formed in vessel segments where blood flow is disrupted, e.g. 
near branch points and curvatures (3). Disease progression can start early in 
life (4), and strong evidence suggests that the process is initiated by the 
infiltration, retention and oxidation of low density lipoprotein (LDL), causing 
fatty streaks in the intima (5). Fatty streaks are not enough to cause any 
symptoms, however persisted inflammation in the vessels can turn fatty 
streaks into larger atherosclerotic plaques (6). Importantly, the lumen 
diameter can remain unaltered by outward remodeling of the vessel wall (7), 
not causing blood flow to be affected. Although this compensation is possible 
to a certain degree, larger lesions will eventually encroach upon the lumen 
and cause stenosis. The severity of the stenosis can also be dependent on 
shrinkage of local vessel segments (8). Vascular stenosis can be 
asymptomatic or cause symptomatic conditions, such as angina pectoris. 
Importantly, atherosclerosis is rarely fatal until a thrombotic occlusion 
appears, usually caused by plaque rupture, exposing pro-thrombotic content 
to the circulating blood (3).  Depending on the location of the obstruction, an 
 1 
The Role of the Autonomic Nervous System in Atherosclerosis 
occluded artery can cause life-threatening events, including stroke, 
myocardial infarction (MI) and heart failure.   
In order to predict CVD outcomes and to develop new treatment methods, 
extensive efforts have been devoted to identifying the underlying risk factors 
for atherosclerosis. The major risk factors are smoking, diabetes, 
hyperlipidemia and hypertension (9). These are often attributed to secondary 
risk factors such as lifestyle and obesity, but also immutable parameters 
including age, heredity and gender. In addition, CVD has been associated 
with other conditions that implicate the autonomic nervous system, such as 
psychosocial stress (10, 11), and autonomic dysfunction (12-14).  
1.2.2 Inflammatory initiation of atherosclerotic 
lesions 
The initiation and progression of atherosclerosis is complex and the 
mechanisms are still not fully understood. As previously described, 
atherosclerosis is initiated by the intimal infiltration and oxidation of LDL. 
Bioactive LDL induces the endothelium to express cell-adhesion molecules, 
such as vascular cell adhesion molecule 1 (VCAM-1), and macrophage 
colony-stimulating factor (M-CSF) (15, 16). As reviewed by Hansson et al. 
circulating leukocytes, predominantly monocytes and T-cells adhere to 
VCAM-1 and enter the arterial intima, a process induced by cytokine 
production from vascular cells (17). Under the influence of M-CSF, 
monocytes differentiate into macrophages with the capability to accumulate 
oxidized LDL (oxLDL) through scavenger receptors (17). Macrophages 
containing intracellular lipids can transform into foamy structures, also 
known as foam cells (18),  which are the major constituents of fatty streaks 
and early lesions (19). oxLDL also binds to Toll-like receptors (TLRs) on 
macrophages, promoting production of pro-inflammatory cytokines, such as 
TNFα (20). Antigen presenting cells, including macrophages, can activate T-
cells by introducing oxLDL through major histocompatibility complex class 
II. Once activated, a main feature of atherosclerotic T-cells is the production 
of interferon gamma (IFNγ) (16), a pro-inflammatory cytokine that further 
activates macrophages and endothelial cells in the vessels (17). Continued 
inflammation accelerates the infiltration and activation of monocytes and T-
cells, promoting fatty streaks to develop into more advanced lesions with a 
lipid-containing necrotic core, covered by a fibrous cap of collagen and 
smooth muscle cells (6). Lesions that are prone to cause thrombosis are 
commonly referred to as vulnerable plaques, and there are numerous factors 
that are considered to indicate such a phenotype, e.g. a thin fibrous cap, 
necrotic core, macrophage density and lesion size (3).       
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1.3 The autonomic nervous system 
The autonomic nervous system (ANS) is the major system responsible for 
homeostasis and in general acts independently of voluntary control. The 
medulla oblongata and hypothalamus accounts for the central parts of the 
ANS, receiving information about the state of the body through afferent 
nerves, and sending compensatory signals through efferent nerves (21). The 
two branches of the ANS are the sympathetic (SNS) and parasympathetic 
nervous system (PNS), two pathways with frequently antagonistic responses 
(22). The major neurotransmitter in SNS is norepinephrine, which binds to 
the α- or β-subtype of adrenergic receptors (23). In the PNS, acetylcholine 
(ACh) is the primary neurotransmitter and binds to different subtypes of 
muscarinic and nicotinic receptors (23).         
1.3.1 ANS in the cardiovascular system 
The cardiovascular system includes the heart and blood vessels, which are 
innervated by both SNS and PNS. The ANS is responsible for maintaining an 
adequate supply of oxygenated blood to different tissues depending on the 
requirements (24). Sensory information about the systems homeostasis is 
mainly detected through two types of receptors. Baroreceptors are located in 
the heart and major blood vessels where they are activated by stretching of 
the vessel wall, deriving from changes in blood pressure. Chemoreceptors are 
mainly located in small clusters, also known as carotid bodies, close to the 
bifurcation of the carotid artery. Chemoreceptors detect the composition of 
circulating arterial blood, mainly the partial pressure of oxygen and carbon 
dioxide (24). Afferent sensory information is received by the nucleus of the 
solitary tract (NTS) in the medulla oblongata, via the vagus nerve, and routed 
to the hypothalamus and the reticular formation (24). In response to received 
information, efferent regulatory output is transmitted to ganglia of the 
specific motor pathways and conveys necessary changes in the cardiovascular 
system (24). For example, increased arterial and venous pressure inhibits 
sympathetic outflow, and activates parasympathetic outflow, resulting in 
reduced heart rate and vasodilation of peripheral vessels, ultimately leading 
to a reduction in blood pressure. In contrast, a decrease in blood pressure will 
have the opposite effects on SNS and PNS, ultimately leading to an increase 
in blood pressure. This reflex is mainly mediated by baroreceptors, and is 
only mildly influenced by chemoreceptor activity (24).  
1.3.2 ANS in cardiovascular disease 
Numerous clinical studies have shown a relationship between modulated 
autonomic function and CVD. Autonomic dysfunction is associated with an 
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elevated risk of cardiovascular events (14), increased  mortality after MI (13, 
25), atrial fibrillation (26), and progression of carotid atherosclerosis, 
independent of other traditional risk factors (12). Although the majority of 
these studies investigate the association between CVD and general ANS 
dysfunction, assessed by measuring heart rate variability using the standard 
deviation of RR-intervals (HRV SDNN), there are studies suggesting reduced 
parasympathetic activity as the main contributor (27).  
Abnormalities can occur in either of the two branches of ANS. Numerous 
studies address the relationship between augmented activity of the SNS and 
increased risk for CVD. Psychosocial stress, such as lack of social support 
and depression, drives sympathetic activity (28), and is  associated with 
cardiac mortality after MI (29). In addition, studies report that psychosocial 
stress prospectively could predict cardiovascular mortality and stroke (30). 
The effects of psychosocial stress have also been investigated in animal 
models, showing accelerated atherosclerosis in cynomolgus monkeys and 
mice living in an unstable environment (31-33). Studies have investigated the 
effects of targeting this route with pharmacological interventions. Inhibition 
of sympathetic drive using treatment with β-adrenergic antagonists (β-
blockers), such as metoprolol, reduces mortality in patients with hypertension 
and heart failure (34, 35). Also, evidence suggests that β-blockers could have 
a direct protective effect on atherosclerosis (36-38).  
It has been reported that the background level of parasympathetic activity 
significantly influences sympathetic control of heart rate. Studies in both 
animals and humans show that increased vagal activity may reduce 
sympathetic drive on the heart (39, 40). The effect of induced 
parasympathetic activity has been further studied in different animal models. 
Vagal stimulation was reported to be antiarrhythmic, and protected against 
ventricular fibrillation and sudden death after MI (41-43). In summary of the 
presented literature, evidence points to an increased risk for cardiovascular 
mortality in the presence of sympathetic drive, and a possible protective role 
for increased parasympathetic activity, yet the mediating mechanisms still 
remain unclear.   
1.3.3 A mediating role for the immune system 
The increased cardiovascular risk in the presence of increased sympathetic 
activity, and the corresponding protective effects of β-blockers, is commonly 
explained by their complex influence on traditional risk factors. Sympathetic 
drive induces a sustained increase in blood pressure (44), one of the major 
risk factors for CVD. However, studies in patients with hypertension and 
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high sympathetic tone shows that the increased risk of coronary artery disease 
can not be fully attributed to blood pressure elevation alone (45), also 
suggesting other links between ANS modulation and CVD, one of them 
being inflammation (46). 
The concept of inflammation is central in atherosclerosis, and suggested to 
provide a mechanistic link between some of the traditional risk factors, such 
as obesity and smoking, and the progression of atherosclerosis (47). 
Interestingly, the conditions discussed in this thesis involving dysregulation 
of the ANS, not only affect CVD and atherosclerosis, but also inflammation. 
Numerous studies report that autonomic dysfunction associates with 
increased levels of inflammatory markers such as the cytokine IL-6, and 
general inflammatory markers C-reactive protein (CRP) and white blood cell 
count (WBCC) (48-51). IL-6 is upregulated in chronic inflammation and 
plays a central role in atherogenic pathways (52), while increased levels of 
WBCC and CRP can predict CVD (53-55), and are directly associated with 
atherosclerosis (56-60). Further, upregulation of the SNS in psychosocial 
stress is reported to be associated with increased proliferation of neutrophils 
and inflammatory monocytes in mice (61), as well as with increased activity 
of nuclear factor-κB (NF-κB) in animals and humans (62, 63). NF-κB 
activates multiple target genes that are associated with the development of 
atherosclerosis (64). Moreover, inhibition of NF-κB attenuates 
atherosclerosis in mice (65).  
It should also be noted that sympathetic blockade has been reported to 
present anti-inflammatory effects. Treatment with β-blockers was associated 
with lower CRP in patients with CAD (66), and reduced levels of 
inflammatory cytokines in patients with dilated cardiomyopathy (67). This 
could possibly be added to the cardio-protective effects of β-blockers.  
In addition to this concept, the last decade provided a number of studies 
describing an anti-inflammatory reflex in response to vagal activity, which 
will be discussed in the next chapter. The evidence for a nerve-driven effect 
on both inflammation and atherosclerosis demands further studies on the 
interrelationship between these factors and the causative direction of proven 
associations.  
1.4 The cholinergic anti-inflammatory pathway 
In the developing field of nerve-driven immunity, convincing data proposes 
an anti-inflammatory response to vagal stimulation, presenting a promising 
target for treatment of inflammatory disease. This route is called “the 
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cholinergic anti-inflammatory pathway” (68),  and emerged in 2000 when 
Borovika et al. showed that acetylcholine attenuated the release of 
inflammatory cytokines in human macrophage cultures, and that TNFα  
production in liver and serum was inhibited by electrical stimulation of the 
vagus nerve in endotoxemic rats (69). Since then, electrical vagal nerve 
stimulation has repeatedly been used to study this route, showing anti-
inflammatory responses in different experimental disease models, such as 
acute cerebral ischemia and reperfusion injuries, sepsis and colitis (70-72).  
1.4.1 The alpha 7 nicotinic acetylcholine receptor 
The alpha 7 nicotinic acetylcholine receptor (α7nAChR) is a ligand-gated ion 
channel forming a homomeric pentamer of α7 subunits, and is one of the 
most abundant nicotinic receptors in the brain (73). Apart from the neuronal 
circuit, α7nAChR have been identified in human immune cells, e.g. 
mononuclear leukocytes (74), B-lymphocytes (75), and basophils and mast 
cells (76).  
Signaling through α7nAChR was early on proposed to play an important role 
in the mechanism of the cholinergic anti-inflammatory pathway (77). Studies 
showed that electrical stimulation of the vagus nerve inhibited TNFα 
production in wild type mice, however this was not achieved in mice lacking 
the α7nAChR (77). The α7nAChR-mediated inhibition of TNFα was further 
attributed to suppression of cytokine-producing macrophages in the spleen 
(77).  
A role of the spleen 
The spleen has been further implicated in the cholinergic anti-inflammatory 
pathway. Experiments have described that splenectomy in rodents abolished 
the inhibitory anti-inflammatory effects of vagus nerve stimulation (70). The 
vagal nerve is not directly linked to the spleen; instead it ends in the celiac-
mesenteric ganglia where it synapses with the sympathetic splenic nerve (78). 
The splenic nerve is solely responsible for the neuronal input to the spleen 
(79, 80), and it has been proposed that cholinergic firing of the vagus nerve, 
ultimately triggers release of norepinephrine in the spleen (81, 82). However, 
the release of norepinephrine fails to explain the activation of α7nAChR on 
splenic macrophages. To assemble this pathway, norepinephrine has been 
proposed to activate β-adrenergic receptors on resident T-cells with ACh-
producing properties (83). Locally synthesized ACh ultimately binds to 
α7nAChR on macrophages, inhibiting their production of TNFα (77). In 
addition, studies also revealed that the α7nAChR is essential for vagus nerve-
mediated norepinephrine release in the spleen (82).  
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α7nAChR in experimental disease models 
Interest regarding α7nAChR in inflammation has emerged in a number of 
different experimental studies using pharmacological agonists to investigate 
possible effects on immune related disease. 3-(2,4-dimethoxybenzylidene)-
anabaseine (GTS-21) is partially selective for α7nAChR, and one of the most 
frequently used agonists. Treatment with GTS-21 has been associated with 
improved outcomes in pancreatitis (84), sepsis (85), and ischemia-reperfusion 
models (86). In addition, the α7nAChR agonist ARR-17779 attenuates 
arthritis in mice (87). Whether these effects are mediated through activation 
of α7nAChR expressed on the celiac-mesenteric ganglia, or directly via 
receptor-activation on immune cells, is not yet determined. The beneficial 
effect of α7nAChR-stimulation in different inflammatory conditions raises 
the question of whether treatment could also improve outcomes in 
atherosclerotic disease. A recent study showed that treatment with the 
α7nAChR agonist PNU-2822987 reduced TNFα, IL-1β, and IL-6 in the heart 
and aorta of spontaneously hypertensive rats (88). Interestingly, these 
cytokines are involved in the pathophysiology of atherosclerosis (16).   
The detailed intracellular-mechanisms of α7nAChR-signaling are still far 
from understood. In vitro studies have indicated that the anti-inflammatory 
properties could be mediated by inhibition of the transcription factor, NF-κB 
(89, 90). Moreover, in vivo models have implicated the Janus kinase-2 and 
signal transducer and activator of transcription 3 (JAK2-STAT3) pathway 
(91), further supported by studies showing that GTS-21 inhibition of cytokine 
production in human whole blood is dependent on JAK2-STAT3 (92).  
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2 AIM 
The overall aim of this thesis was to investigate the role of the autonomic 
nervous system in the development of atherosclerosis. Our particular focus 
has been to test the hypothesis that inflammation is a mediator in this 
relationship, and that the cholinergic anti-inflammatory pathway is an 
important regulator in this context.   
In this thesis, we specifically aimed to investigate:  
 
- If autonomic dysfunction is related to atherosclerosis due to 
an independent association with inflammation (Paper I) 
 
- If the athero-protective effect of sympathetic blockade with 
metoprolol involves inhibition of atherogenic cytokine 
production in mice (Paper II) 
 
- If α7nAChR-deficiency increases atherosclerosis, and if 
stimulation of α7nAChR decreases atherosclerosis (Paper III 
and IV) 
 
- If α7nAChR is localized in human carotid tissues and have a 
functional role in human blood cells (Paper III and IV)  
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 Study populations and biopsies 
All studies on human subjects were conformed according to the ethical 
guidelines of the 1975 Declaration of Helsinki, and reviewed and approved 
by regional ethical boards. All subjects gave written informed consent to 
participate in the studies. 
3.1.1 Patients under investigation for carotid 
atherosclerosis (Paper I) 
Male patients (n=124, ≥40 years), under investigation for carotid 
atherosclerosis were enrolled from Western Region Initiative to Gather 
Information on Atherosclerosis (WINGA, http://wlab.gu.se/bergstrom/winga) 
to further investigate autonomic function and inflammatory status. WINGA 
provides records of patients undergoing diagnostic carotid ultrasound 
examinations due to minor stroke- or TIA-suspected symptoms within the 
Gothenburg region in Sweden. Subjects with rheumatoid disease, WBCC 
above 30x109 cells/L, CRP above 10 mg/L, or unsuccessful assessment of 
autonomic function were excluded.  
3.1.2 Carotid plaque specimens for histology (Paper 
III) 
Patients with symptomatic and severe carotid plaques can be treated by 
endarterectomy, a surgical procedure to remove atherosclerotic material from 
the aortic wall. Several clinical trials concluded that the degree of stenosis is 
relevant for risk assessment in these conditions, and endarterectomy is 
suggested to patients with a stenosis degree of more than 80% (93). 
Atherosclerotic carotid specimens from this type of surgeries were provided 
to us from the Göteborg and Umeå Vascular study group (GUVASC, 
http://wlab.gu.se/bergstrom/guvasc) for histology (n=10).    
3.1.3 Gene profiling in human plaques (Paper III)  
The Biobank of Karolinska Endarterectomies (BiKE) at Karolinska 
University Hospital, Stockholm, Sweden, was used for analysis of gene 
expression in atherosclerotic specimens (n=107). BiKE contains information 
on RNA, DNA, in situ and in vitro analysis of atherosclerotic specimens, 
clinically removed based on the same criteria as described above. In addition, 
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the BiKE-database also provides plentiful clinical information, such as 
medications and anthropometric data.   
3.1.4 Blood samples from healthy subjects (Paper IV) 
Blood samples for in vitro stimulations were collected from healthy donors of 
mixed age and gender (n=12), from the blood bank, Droppen, at the 
Sahlgrenska University Hospital in Gothenburg. All subjects were non-
smokers.   
3.2 Assessment of autonomic function (Paper 
I) 
Paper I assessed the relationship between autonomic function, inflammation 
and atherosclerosis by measuring the cardiac response to input from the 
autonomic nervous system (ANS). In the absence of sympathetic or 
parasympathetic input, the sinus node has an intrinsic rate of depolarization, 
producing an intrinsic heart rate (94). In reality, heart rate is dynamically 
affected by input from the ANS, determining the real heart rate (95). Heart 
rate variability (HRV) and baroreceptor sensitivity (BRS) are well 
established, and the most frequently used methods, to assess the dynamic 
autonomic function in regulating cardiac frequency. 
3.2.1 Heart rate variability 
HRV is the physiological variation in heartbeat intervals and can be assessed 
by a number of different methods. HRV measurements in the time domain 
evaluates the QRS complex intervals from continuous electrocardiography 
(ECG) recordings, ranging from 5 minutes to 24 hours (96).  In Paper I, HRV 
was assessed using short-term recordings of 20 minutes in supine position, 
and analyzed by calculating the standard deviation of RR-intervals (SDNN). 
HRV-measurements can reflect different types of input from the autonomic 
nervous system. However, SDNN is commonly used as a marker for both 
sympathetic (SNS) and parasympathetic activity (PNS) (96).  
3.2.2 Baroreceptor sensitivity 
The arterial baroreflex is the physiological response of heart rate and vascular 
resistance after acute changes in blood pressure (BP). Baroreceptors are 
constantly providing the central nervous system with information on changes 
in BP, dynamically modulating the ANS to minimize the variations (97, 98). 
A rise in BP increases PNS-activity and decreases SNS-activity, resulting in 
decreased heart rate, contractility and peripheral vascular resistance.  In 
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contrast, reduced BP will have the opposite effects. In paper I, function of the 
baroreflex was evaluated by measuring spontaneous BRS in the time domain. 
Spontaneous BRS is defined as the change in heart rate in response to 
spontaneous changes in BP. BRS was assessed with the sequence method, 
where three consecutive heart beats with the RR-interval following a change 
in BP defines a sequence (99).  Each sequence was analyzed by linear 
regression, and the average was calculated. The response time between the 
PNS and the SNS is significantly different, with an almost immediate 
response for the PNS and a slower response for the SNS (100). Thus, this fast 
beat-to-beat measure of BRS is regarded as marker of parasympathetic 
function (100).  
3.3 Clinical parameters (Paper I) 
To establish whether a factor independently can predict an outcome, it is 
necessary to adjust for other possible co-founders. In Paper I, we aimed to 
investigate if there was an independent association between autonomic 
function and inflammation, and between inflammation and carotid 
atherosclerosis. Thus, traditional risk factors for both inflammation and 
atherosclerosis were adjusted for, including prevalent CVD, diabetes, 
smoking, body mass index, hypertension, systolic blood pressure, 
cholesterol-lowering medicine, age and antihypertensive medicine. 
3.4 Animal models of atherosclerosis (Papers 
II-IV) 
Medical research uses mice extensively because of their many advantages, 
including quick reproduction, small size, easy maintenance, low costs, and 
well-characterized genetic background. However, mice do not spontaneously 
develop atherosclerotic lesions, and need to be genetically modified before 
they can be used in experimental models. The reason for this is probably that, 
in contrast to humans, circulating cholesterol in mice is high in LDL and low 
in HDL (101-103). By deletion of specific genes the lipid profile can be 
altered, providing strains that are prone to developing atherosclerosis. Mice 
are convenient to use in studies of diseases with slow progression, due to 
their short life span. In humans, atherosclerosis is a disease with a slow 
development, starting early in life and eventually leading to clinical events 
late in life. In mouse models, severe atherosclerosis can be developed in a 
couple of weeks instead of decades. One of the limitations with mice is that 
the small size of the animal prevents extensive collection of tissue and 
sample volumes. 
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3.4.1 Atherosclerosis-susceptible mouse strains  
In atherosclerosis studies, two of the most commonly used mouse models are 
the apolipoprotein E-deficient (ApoE-/-) mouse and the low-density 
lipoprotein receptor deficient (LDLr-/-) mouse. Both models have been used 
in this thesis.  
ApoE-/- Mice (Papers II and IV) 
In 1992, the ApoE-/- mouse was the first genetically modified strain to be 
introduced in our research field (104). Apolipoprotein E (APOE) is a 
cholesterol and lipid carrier protein, essential for lipid metabolism (105).  
APOE-deficiency provides a mouse model with spontaneous 
hypercholesterolemia, especially in remnants of VLDL and 
chylomicrons(104, 106), and atherosclerosis (101, 104, 106). A drawback 
with the ApoE-/- mouse is that the lipid profile is different from humans, 
where most of the plasma cholesterol is transported as LDL. Importantly, 
initiation and progress of atherosclerosis with fatty streaks developing into 
advanced plaques with a fibrous cap appears to resemble the morphological 
features seen in human atherosclerosis (107). Since the primary focus of this 
thesis was to characterize the development of atherosclerotic lesions, ApoE-/- 
mice were used in Paper II and IV. 
LDLr-/- Mice (Paper III) 
In contrast to ApoE-/- mice, cholesterol-enriched food is necessary for LDLr-/- 
mice to develop hypercholesterolemia and atherosclerosis. The LDLr is 
expressed on liver cells and is important for clearing the blood of lipoprotein 
particles, by binding to APOE. Unlike ApoE-/- mice, LDLr-/- mice display a 
lipid profile that is more similar to humans, where cholesterol is mainly 
confined to the LDL fraction (108). The morphology of early stage 
atherosclerosis is considered to resemble the human counterpart, however 
late stage atherosclerosis has not been fully described (109). LDLr-/- mice are 
preferable in bone marrow transplantation (BMT) studies, which will be 
further discussed in a subsequent chapter. Thus, LDLr-/- mice were used in 
Paper III.  
3.4.2 Diet induced hypercholesterolemia (Papers II-
IV) 
LDLr-/- mice has to be fed a cholesterol-enriched or high fat diet in order to 
develop atherosclerosis, and even though ApoE-/- mice spontaneously 
develop plaques, this process can be further accelerated by such food 
manipulations (106). The cholesterol-enriched diet used in Paper III contains 
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15% fat and 1.25% cholesterol, whereas the high fat diet in Paper II and IV 
contains 21% fat and 0.15% cholesterol.  
3.4.3 α7nAChR deficient mice (Paper III) 
Different methods are used to investigate the physiological role of a protein 
in mice. One of the common techniques is to over- or under-express the 
protein of interest and compare the physiological response to control mice. 
To investigate the role of a protein in the development of atherosclerotic 
lesions the expression needs to be modified in atherosclerosis-prone mice. In 
this thesis, the functional role of the α7nAChR was investigated in under-
expressed LDLr-/- mice.  
Bone marrow transplantation (Paper III) 
Bone marrow transplantation (BMT) transfers the hematopoietic genotype 
from a donor to a recipient. The transferred genotype will only be adopted in 
bone marrow-derived cells, and the original genotype remains unaltered in all 
other cells. Since the atherogenic effect of LDLr-deficiency derives from its 
expression on liver cells, LDLr-/- mice are well suited for BMT, with the 
advantage that the donor does not need to be LDLr-/- for the mouse to develop 
atherosclerosis. After BMT in LDLr-/- mice, it takes about 8-12 weeks for the 
white blood cell count return to normal (110). It is reported that LDLr-/- mice 
after BMT display larger plaques in the aortic root, but smaller plaques in the 
thoracic aorta, compared to LDLr-/- mice unexposed to BMT (110). This is 
important to remember when comparing lesion morphology with studies 
using other techniques for protein depletion. In Paper III, recipient bone 
marrow was depleted with 2 doses of irradiation, then received bone marrow 
from α7nAChR-/- mice or wild type mice (WT), and recovered for 4 weeks 
before being fed a cholesterol-enriched diet.   
Double-knockout mice (Paper III) 
A common method to create a mouse with the characteristics of two or more 
transgenic models is by cross breeding. These mice will eventually express 
the combined genotype, which can be further maintained in a breeding 
facility. In Paper III, an atherosclerosis-prone mouse with α7nAChR 
deficiency was used by cross breeding homozygous (-/-) LDLr mice with 
heterozygous (+/-) α7nAChR mice. An LDLr-/-/α7nAChR+/- breeding 
generates offspring where all mice are LDLr-/- but can be either homozygous, 
heterozygous or wild type (+/+) for α7nAChR. The great advantage with a 
heterozygous breeding is that you will have littermate controls for your   
double knockout (KO) mice, avoiding the risk of genetic drift, thus providing 
more reliable comparisons than when using WT mice from a separate 
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breeding (111). However, the method generates extra burden and lower yield 
than maintaining separate breeding for KO- and WT -mice. 
3.5 Drug administration (Papers II and IV) 
Reliable drug administration is crucial to ensure appropriate concentrations 
and the desired response throughout the experimental period. The preferred 
route of administration is dependent on many factors, e.g. pharmacokinetic 
properties of the substance, site of action, and duration of the treatment 
period. Animal experiments on atherosclerosis usually expand over weeks to 
months. The duration of these experiments makes administration techniques 
with low researcher interventions favorable, such as implanted minipumps or 
administration via food and drinking water.  Injections are invasive, and 
usually need to be repeated at a high frequency to maintain a steady 
concentration.  Besides being time consuming, and causing repeated 
disturbance to the animals, there is also a risk of injecting the drug into the 
wrong compartment. Independent of drug administration methods, successful 
treatment is preferably verified by drug concentration measurements.  
3.5.1 Osmotic minipumps (Papers II and IV) 
In Paper I and IV (8-week study), metoprolol or α7nAChR-agonist were 
administered by subcutaneous implantation of osmotic minipumps on the 
back of the mouse, through a small incision on the neck. The operation was 
performed during 5-10 minutes of anesthesia with isoflurane, and 
buprenorphine for postoperative analgesia. Osmotic minipumps have the 
benefit of continuously delivering an even amount of drug so that steady state 
concentrations can be achieved. Even though the method is invasive, no 
further interventions are necessary after the implantation. A disadvantage 
with osmotic minipumps is the short duration of 4-6 weeks, necessitating 
replacement of the pumps during long-term experiments. In this thesis, 
minipumps were replaced once during the experiments.    
3.5.2 Drug-admixed food method (Paper IV) 
In Paper IV, the drug-admixed food method was used to give the α7nAChR-
agonist in the 12-week study. Drug-admixed food is a non-invasive method 
with the advantage of not disturbing the animals during the treatment period. 
The drug can be mixed into the appropriate diet and fed to the mice using 
ordinary routines. A disadvantage with drug-admixed food is that the 
appropriate dose is calculated based on the estimated food intake, and any 
deviation in consumption can affect the desired effect, or cause variations in 
exposure between the animals. This can be controlled for during the 
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experiment by measuring food consumption, but requires mice to be in 
separate cages. This type of control was used in Paper IV. 
3.6 Physical stressor (Paper II) 
In Paper II, the appropriate dose of metoprolol was verified by a dose-
response study on the heart rate effects after air-jet induced stress. Mice were 
placed in a special cage where they were repeatedly exposed to jet streams of 
compressed air for randomized time and recovery periods (2-10 min) for a 
total duration of 2 hours. This method has previously been shown to 
effectively increase both heart rate and blood pressure (112).  
3.7 Electrocardiography in mice (Paper II) 
Anesthesia is associated with depressed autonomic control and basal cardiac 
function, i.e. reduced heart rate (113). Therefore, heart rate is preferably 
measured in conscious mice during cardiovascular experiments, and 
telemetry has become the gold standard in blood pressure measurements 
(114). In paper II, ECG with radiotelemetry transmitters was used to measure 
conscious heart rate in mice. Transmitters were implanted in the abdomen 
and ECG electrodes were placed under the skin. Recordings were conducted 
in freely moving mice by detectors placed under the cage. An advantage with 
radiotelemetry, in comparison to non-invasive methods is that no restrain of 
the animals is needed, and there is no disturbance from researchers during the 
measurements which provides reliable data (115). Disadvantages are the 
demand for surgical skills and expensive equipment.  
3.8 Histology 
Histology is an essential technique to examine the morphology of a 
specimen, or the distribution and localization of proteins and cells in a tissue.  
The examination is conventionally performed under a microscope, usually 
after a preservative treatment, and enhances visualization of structures using 
different staining techniques.  
3.8.1 Atherosclerosis quantifications (Papers II-IV) 
The assessment of atherosclerosis is usually determined by either en face 
quantification in the aorta, or cross-sectional quantification in the aortic root. 
Both methods are based on the staining of lipid deposits in the plaques, 
providing a better definition of the lesions. The degree of atherosclerosis in 
different parts of the aorta have been reported to show a strong correlation in 
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some studies (116), while other studies indicate only a weak correlation 
(102). If possible, quantifications in different compartments can be of value. 
In order to compensate for differences in vessel size, the amount of plaque is 
usually normalized to the total area of the aorta, or to the circumference of 
the aortic root.  
En face quantification (Paper II and IV) 
To perform en face quantification lipids are stained on the intimal surface of 
an open vessel. This method only gives a 2-dimensional assessment of a 3-
dimensional structure and no information on height, composition or 
developmental stage. In Paper II and IV, en face quantifications were 
performed in longitudinally opened thoracic aortas, and stained with Sudan 
IV for lipids.  
Cross-sectional quantification (Papers II-IV) 
A cross-sectional quantification is conventionally conducted in serial sections 
of a vessel. This technique allows for more extensive and volumetric 
measurements on the severity of atherosclerosis, including the height of the 
plaque and how much of the vessel lumen is covered by lesions. Another 
advantage is the possibility to investigate the morphology, developmental 
stage, and immunological composition of the plaques using different staining 
techniques. In Paper II-IV, cross-sections from 6 (Papers II and IV) or 8 
(Paper III) different levels, 100-800 μm from the aortic sinus, were stained 
with Oil Red O for lipids.  
3.8.2 Immunohistochemistry (Papers II-IV) 
The first immunohistochemistry study was reported in 1942 (117), and has 
now become one of the most frequently used methods to identify and 
quantify proteins in tissue. Immunohistochemistry involves the use of 
biochemical and immunological techniques to visualize a protein through the 
binding of a target-specific antigen to a labeled antibody. The choice of 
antibody is essential, and they are produced to be either polyclonal or 
monoclonal. Both types have their separate advantages and disadvantages 
(118, 119). Polyclonal antibodies detect multiple epitopes on the antigen with 
the advantage of a stronger signal due to multiple binding sites. Affinity for 
multiple epitopes also provides these antibodies with higher tolerance for 
changes in the antigens. However, polyclonal antibodies are in general less 
specific due to cross-reactivity and can have a large batch-to-batch 
variability. Monoclonal antibodies are aimed at a single epitope on the 
antigen with the advantage of increased specificity, and low background. 
However, monoclonal antibodies are sensitive to chemical influence to the 
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epitope, for example caused by fixation. In the direct method, the primary 
antibody is already labeled and can be detected in a microscope without 
further processing. The indirect method involves the use of a secondary 
antibody, directed against the IgG of the animal species in which the primary 
antibody was produced. This allows for the flexibility of using different 
detection methods using the same primary antibody. The secondary antibody 
can be labeled with a fluorochrome, or an enzyme that can be further 
oxidized by a substrate to produce colorimetric stainings.   
Immunoperoxidase (Papers II-IV) 
In this thesis, immunoperoxidase staining has been used to characterize the 
atherosclerotic plaque composition, or receptor localization in humans (Paper 
III) and mice (Paper II-IV). A biotinylated secondary antibody was added to 
the specimens after incubation with the primary antibody, followed by 
Vectastain ABC reagent (Vector Laboratories). Vectastain ABC reagent 
forms an Avidin/Biotin enzyme complex with the biotin on the secondary 
antibody, and can be detected in a brightfield microscope after a reaction with 
an organic substrate. In this thesis, either 3,3´–Diaminobenzidine (DAB), or 
NovaRED (Vector Laboratories) was used for colorimetrical detection. 
Depending on the type of marker, the target was quantified by either counting 
the total number of positive stained cells, or by a software filter that measures 
the stained area.  An advantage with peroxidase stainings is the possibility to 
get a structured overview of the tissue, thus providing the location of the 
target to recognizable areas and structures.  
Immunofluorescence (Paper III) 
Immunofluorescence allows for the detection of several antibodies in the 
same specimen. Primary antibodies are labeled with different fluorochromes, 
either direct or indirect as described earlier, and can be detected in a light 
microscope with different filters. Since the secondary antibodies must bind 
specifically to their respective target, primary antibodies from different host 
species are recommended for indirect labeling. In this thesis, the investigation 
of α7nAChR expression on different immune cells was accomplished using 
double staining with indirect labeling in human plaques. The images captured 
of each target were merged together, and possible co-localization between a 
certain cell type and the receptor was determined. This is also the great 
advantage with immunofluorescence, the technique allow for investigating 
co-localization between different targets.  
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3.9 RT-qPCR (Paper III and IV) 
The polymerase chain reaction (PCR) was first developed in the 1980s (120), 
and was a revolutionary method used to examine gene expression. In 
traditional PCR, DNA is amplified and detected in an end-point analysis. 
Since then, the development of real-time PCR (qPCR) allows quantification 
of the product, not only at the end of amplification, but after each cycle. 
qPCR is considered to be a reliable method with the advantages of high 
sensitivity and precise measurements (121). In Papers III and IV, the 
expression of messenger RNA (mRNA) for different atherosclerosis-
associated markers was analyzed with qPCR using reverse transcription (RT-
qPCR). In RT-qPCR, mRNA is used as the starting material. RNA is further 
transcribed into complementary DNA (cDNA) by the enzyme, reverse 
transcriptase. In the following PCR-reaction, cDNA is degenerated into a 
single-stranded molecule by heating to 95 °C, and allows primers to be 
incorporated when lowering the temperature. Primers for the mRNA of 
interest provide a specific amplification of the corresponding sequence of 
cDNA by again raising the temperature to around 70°C, and can be 
quantified by a bound fluorescent dye. This process can be repeated, and for 
each amplification cycle, the amount of cDNA doubles together with the 
fluorescent signal. An important consideration in running RT-qPCR is to 
validate the mRNA quality and efficiency of the reverse-transcription 
reaction, for both target genes and also for the reference genes (122). 
Reference genes are also used to normalize the obtained data (123).  The 
choice of reference gene is usually determined by including multiple 
housekeeping genes when setting up a new experimental assay.  The 
housekeeping genes with the most stable mRNA expression are used for 
normalization. In this thesis, the stability of a number of reference genes was 
evaluated for each study and specimen, and the applicable one chosen 
accordingly.  
3.10 Microarray technology (Paper III) 
Although RT-qPCR is a reliable and convenient method to measure mRNA 
for a limited number of targets, large gene expression profiles are better 
accomplished using other methods. To investigate cellular pathways and 
complex interactions, the characterization of thousands of targets is 
sometimes necessary. Microarray technology is one way to accomplish this, 
by measuring mRNA levels of many genes at the same time (124). 
Microarray technology is based on chips that can be labeled with a large 
amount of probes, making them sufficient to perform genome-wide mRNA 
profiling (124).  In Paper III, we analyzed the BiKE-database (described 
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above) for the expression pattern of Chrna7 mRNA in human carotid plaques. 
The genome-wide mRNA expression profile in BiKE has been obtained 
using the Affymetrix’s GeneChips technology.     
3.11 Flow cytometry (Paper III and IV) 
In Paper III and IV, cell populations in the spleen were analyzed with laser-
based flow cytometry, a powerful method to characterize individual cells in a 
single cell suspension by their different properties. With high-throughput, 
each cell in the suspension passes through a flow cell where physical 
properties such as size and granularity are measured by their exposure to 
laser beams. The reflection of the laser beams scatters differently depending 
on cell properties. Scattered light is detected by photodiodes and digitally 
converted for further computer processing. The full capacity of flow 
cytometry manifests when this method is combined with fluorescence-labeled 
antibodies. Antibodies directed at different cell targets allow for customized 
panels with the appropriate read-out for the experiment. Multiple 
fluorochromes can be detected simultaneously, only limited by the number of 
different lasers and fluorescence detectors installed in the system.  Evoked 
fluorescence is routed via a system of beam-splitters, usually dichroic 
mirrors, and wavelength-specific filters before detection in the correct 
photomultiplier tube (PMT). The system uses a single PMT for each spectral 
wavelength, and when the emitted photons strike the corresponding PMT, the 
signal is weak. Importantly, the photons are converted into electrons that are 
multiplied in the PMT and further amplified into a voltage pulse. The size of 
the voltage pulse corresponds to the number of detected photons and can be 
stored and analyzed in a computer system after digital conversion. In Paper 
III, cells were examined using a flow cytometer (FACSCantoA, BD 
Biosciences) with 2 lasers. Flow cytometry has the advantages of cell-by-cell 
characterization of antigen expression and physical properties in large cell-
populations with high-throughput, at a reasonable cost. This technique can be 
used for any tissue where single-cell suspension can be achieved. A 
disadvantage is that the need for single-cell suspension complicates the 
analysis of “sticky” cells. It should also be mentioned that a fluorophore used 
in flow cytometry emits photons of multiple wavelengths. This can cause a 
spillover effect of photons from the designated PMT into a detector with 
filters in the nearby wavelength range.  To overcome the problem of 
unwanted signals, compensation controls for the included fluorophores are 
used to correct for the amount of spill over.  
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3.12 Proliferation assay (Paper III) 
A commonly used assay for measuring cell proliferation is the thymidine 
incorporation assay, where the radioactive nucleoside 3H-thymidine is 
incorporated into new strands of DNA. Cultured cells are usually triggered 
with a mitogen to induce proliferative properties. The amount of radioactivity 
in a cell culture corresponds to the degree of cell division and is commonly 
assessed by measuring β-particles with a scintillation counter.  
In Paper III, splenocyte proliferation was investigated after stimulation with 
the T-cell mitogen, concanavalin A. Thymidine was added to cultured cells 
48 hours after concanavalin A stimulation, and incubated for another 18 
hours at 37°C, 5% CO2, before measuring radiation. Precaution should 
always be used when working with radioactive molecules. 3H-Thymidine can 
be toxic and inflict chromosomal changes and cell death (125). Without 
proper facilities or manageable handling and waste of radioactive 
compounds, the thymidine analog bromodeoxyuridine (BrdU) can be used as 
an alternative (126). Instead of measuring radioactivity, 
immunohistochemistry or flow cytometry can be used to detect BrdU. 
However, in immunohistochemistry the signal needs to be amplified, which 
can cause unreliable data (127). 
3.13 Ex vivo treatment of human blood (Paper 
IV) 
Ex vivo stimulations of whole blood is an effective method to examine 
cytokine production in response to treatment with different compounds.  
In Paper IV, human blood from healthy donors was stimulated with 
lipopolysaccharide (LPS) and treated with an α7nAChR-agonist. After 4 h of 
incubation in 37 °C, samples were centrifuged and serum was analyzed for 
inflammatory cytokines. In addition to whole-blood assays, in vitro 
stimulations are commonly performed in peripheral blood mononuclear cells 
(PBMC). However, the isolation of PBMCs is more labor-intensive and 
requires larger sample volumes. In addition, studies show that experiments in 
whole blood provide higher cell viability, compared to PBMCs (128), and 
that cells in a serum-free environment react differently compared to cells in 
serum-supplemented medium (129). The use of whole blood for in vitro 
experiments have the advantages of being a low cost method, reflect the 
circulating environment, and mimicking the in vivo response (130). 
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3.14 Biochemical analysis in mice  
3.14.1 Systemic drug exposure (Paper II and IV) 
Verification of drug exposure is important in all pharmacological studies. 
Depending on the method of administration, the reliability of the exposure 
varies. Subjects or animals failing to receive the desired concentration should 
be excluded from the study. In this thesis, systemic concentration of 
metoprolol in serum (Paper II), and of α7nAChR-agonist in whole blood or 
plasma (Paper IV), was measured with liquid chromatography-mass 
spectrometry (LC-MS). An advantage of LC-MS is its high sensitivity and 
the possibility of analyzing tiny amounts of a substance, allowing for non-
terminal measurements where the sample volume is limited, such as in Paper 
IV.  
3.14.2 Total cholesterol (Paper II-IV) 
In this thesis, total cholesterol was assessed colorimetrically in serum (Paper 
II-IV) or in plasma (Paper IV, 12 week study), using the enzymatic 
colometric kit according to manufacturers protocol (RANDOX Laboratories 
Ltd., Crumin, UK) and subsequent detection in a spectrophotometer. 
3.14.3 Cytokines   
The measurement of cytokines is frequent in studies where inflammation is 
central. Enzyme-linked immunosorbent assays (ELISA) are widely used and 
enables reliable and sensitive measurement of the target (131). Although the 
method is reasonably cheap and effective, it is limited to measuring one 
cytokine per sample. Since atherosclerosis is a complex process, involving 
numerous cytokines (16), single measurements are not always satisfying. 
Repeated measurements with ELISA are expensive, time consuming and 
demands large amount of sample volume. Under these circumstances, 
multiplex assays are a convenient option that allow to measure numerous 
cytokines at the same time, saving money, time and sample volume.  
TNF-α, IL-1β, and IL-6 (Paper III and IV) 
Human serum levels of TNFα, IL-1β, and IL-6 (Paper IV), and supernatant 
levels of TNFα from the mouse splenocyte proliferation assay (paper III), 
were measured with colorimetric ELISA. In this thesis, human samples were 
analyzed using ELISA MAXTM (eBioscience, Inc. CA, US), and mouse 
samples using an ELISA kit (RandD Systems, MN, USA) according to 
manufacturer’s protocol. A spectrophotometer was used to further detect and 
calculate sample concentrations after enzymatic reactions.  
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Th1/Th2 cytokines (Paper II) 
In paper II, a mouse Multiplex ELISA (Meso Scale Discovery, MD, US) was 
used to measure Th1 (IL-1β, IL-2, IL-12, IFNγ, TNFα, and CXCL1) and Th2 
(IL-4, IL-5 and IL-10) cytokines, according to the manufacturer’s protocol.  
3.15 Statistics 
In this thesis, all data was assessed for normality using Shapiro-Wilk´s 
normality test and the appropriate statistical method chosen accordingly. In 
some analysis, skewed data was logarithmically or arcsine transformed to 
achieve normal distribution. In all cases, untransformed data was presented 
for better comparison with other studies. Univariate associations were 
analyzed with Pearson´s correlation (Paper I and III). Atherosclerotic lesion 
areas in different levels of aortic root were analyzed with repeated 
measurement two-way ANOVA (Paper III and IV).  
In paper I, comparisons between patient categories were analyzed with 
Student´s t-test for continuous variables and Chi-square test for categorical 
variables. For mediation analysis, multiple regressions including 2 predictors 
were used. Independent associations were investigated using multiple 
regressions with stepwise adjustment (selection of p<0.05) for other clinical 
predictors. In paper II, 24-hour heart rate was analyzed with repeated 
measurement ANOVA, followed by Dunnet’s post hoc test. In paper III, flow 
cytometry and proliferation experiments were conducted and terminated at 
two different time-points. Thus, this data was analyzed using two-way 
ANOVA, with experiment as a co-variate, and presented as estimated 
marginal means ± SEM. Mean lesion area in the aortic root was analyzed 
using Student’s t-test. In Paper IV, mean lesion area in aortic root and 
thoracic aorta was analyzed using Students t-test. Stimulations in human 
samples were conducted by stimulating blood from the same subject with 
different stimuli and internal controls. Thus, this data was analyzed with 
repeated measurement one-way ANOVA followed by Holm’s sequential 
Bonferroni correction. Gene expression was analyzed with Mann Whitney-U 
test, including Holm’s sequential Bonferroni. For data not already mentioned 
in this section, Mann Whitney U-test was used for statistics. 
In this thesis, if nothing else was discussed, all human data was expressed as 
mean ± SD, and all mouse data as mean ± SEM. P<0.05 was considered as 
statistically significant in all analysis except for Th1/Th2 cytokines in Paper 
II, where the level of significance was considered at P<0.01, to reduce the 
risk of mass significance. 
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4 RESULTS AND DISCUSSION 
4.1 The link between autonomic dysfunction, 
inflammation and atherosclerosis (Paper I) 
Studies prior to this thesis have reported that autonomic dysfunction 
associates with both inflammation (48-51), and CVD (13, 14). Further, 
numerous studies describe low-grade inflammation as a risk factor for CVD 
(53-55). Surprisingly, few studies have investigated if autonomic dysfunction 
is directly related to CVD, or if inflammation could mediate this association, 
and to our knowledge, never with carotid atherosclerosis as the primary 
endpoint. In paper I, we studied these conditions in men under investigation 
for carotid atherosclerosis by assessing two markers of autonomic function 
(BRS and HRV SDNN), and two markers of inflammation (WBCC and 
CRP).  
In an initial analysis we found that subjects with prevalent CVD, defined as 
stroke or MI, exhibited reduced BRS, increased levels of WBCC and 
augmented carotid atherosclerosis compared to subjects with no history of 
CVD (Table 1). There were no differences in HRV or CRP (Table 1). 
Although HRV and CRP did not prove a difference between the groups, this 
data indicates that autonomic function is reduced, and inflammation is 
increased in subjects with prevalent CVD, prompting us to further investigate 
the associations between these conditions. Since rupture of atherosclerotic 
plaques is the major cause of MI and stroke (17), and our data showed an 
increased burden of carotid atherosclerosis in subjects with prevalent CVD, 
we chose to use this as our cardiovascular endpoint in subsequent analysis. In 
our study, prevalent CVD was regarded to be present in subjects with a 
history of stroke or MI. The relevance for carotid atherosclerosis in MI could 
be debated.  Importantly, it has been shown that the presence of carotid 
atherosclerosis is directly correlated with the extent of coronary 
atherosclerosis (132), and carotid bruits is an important predictor for MI and 
myocardial mortality (133).  
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Table 1. Characteristics of population and comparison between subjects with or without 
prevalent CVD 
Variable All  No history of 
CVD 
Prevalent 
CVD 
P* 
Carotid plaque area, mm2 58.3 ± 51.6 44.1 ± 40.4 73.0 ± 57.9 <0.001 
CRP, mg/L 1.81 ± 1.7 1.72 ± 1.61 1.91 ± 1.77 0.3 
WBCC, cells 109/L 6.1 ± 1.6 5.8 ± 1.6 6.4 ± 1.7 0.040 
HRV SDNN, ms 44.3 ± 18.4 45.9 ± 17.9 42.7 ± 18.9  0.3 
BRS ms/mm Hg 11.1 ± 6.8 12.8 ± 7.9 9.5 ± 5.1 0.022 
Values expressed as means ± SD. CRP: C-reactive protein, WBCC: White blood cell count, 
HRV: Heart rate variability, SDNN: Standard deviation of RR interval, BRS: Baroreceptor 
sensitivity. 
We investigated possible predictors for carotid plaque area using bivariate 
correlations. Carotid plaque area was positively correlated with WBCC and 
CRP, and inversely correlated with BRS (Figure 1A). No significant 
association between HRV SDNN and carotid plaque area was found (r=-0.16, 
P=0.081). For the inflammatory markers, CRP was inversely correlated with 
BRS (r=-0.23, P=0.009), and WBCC was inversely correlated with both BRS 
(r=-0.29, P=0.001) and HRV SDNN (r=-0.22, P=0.014). Taken together, this 
data suggest that both autonomic dysfunction and inflammation associates 
with atherosclerosis in this population. We can only speculate why only BRS, 
and not HRV SDNN, inversely associates with atherosclerosis. One 
explanation could be that HRV SDNN is regarded as a general marker for 
autonomic function (96), whereas BRS is regarded as a marker of 
parasympathetic function (100), potentially reflecting different aspects of the 
ANS. If the parasympathetic branch of the ANS is the major contributor to 
the relationship between ANS-dysfunction and atherosclerosis, HRV SDNN 
may be too blunt to detect such association in this population. In addition to 
the data presented in this section, other predictors for atherosclerosis and 
inflammation were also assessed with bivariate correlations  (Table 2, Paper 
I).    
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Figure 1. Relationships between autonomic function, inflammation and carotid plaque area. r-
values in the univariate models are Pearson correlation coefficients (A) and β-values in 
mediator and adjusted models are standardized regression coefficients (B,C,D). Mediator 
models are multiple linear regressions including one variable of autonomic function and one 
variable of inflammation (B, C). Adjusted models are multiple linear regressions, adjusted for 
prevalent CVD, diabetes, smoking, BMI, hypertension, systolic blood pressure, cholesterol-
lowering medicine, age and antihypertensive medicine (D). CRP: C-reactive protein, WBCC: 
White blood cell count, HRV: Heart rate variability, SDNN: Standard deviation of RR-
interval, BRS: Baroreceptor sensitivity.  
To investigate whether the association between BRS and carotid plaque area 
is direct or mediated via inflammation, 2-predictor multiple linear regression 
models were used to adjust for the inflammatory markers. When adjusted for 
either WBCC, or CRP, the association between BRS and carotid plaque area 
was attenuated (Figure 1B and C). WBCC and CRP still remained 
significantly associated with carotid atherosclerosis after adjustment for BRS 
(Figure 1B and C). This indicates that inflammation, at least partly, could be 
mediating the effects of autonomic dysfunction on atherosclerosis. However, 
the role of CRP as a mediator should be cautiously interpreted since the 
attenuation was weak. Also, even though this data propose the internal order 
of this pathway to be autonomic dysfunction-inflammation-carotid 
atherosclerosis, the causal direction of this link cannot be determined in our 
study. There are reports, both supporting and opposing, that the presence of 
carotid atherosclerosis could have an impact on BRS (134, 135). However, 
these studies are rarely adjusting for inflammation, a predictor of aortic 
stiffness (136, 137). 
Given the suggested relationship between BRS, variables for inflammation 
and atherosclerosis, the independency of theses associations were 
investigated by adjusting for other potential confounders. After full 
adjustment for age, medication, prevalent CVD, smoking, BMI, diabetes, 
dyslipidemia and systolic blood pressure, WBCC and CRP was still 
independently inversely associated with BRS (Figure 1D). Further, carotid 
plaque area still remained independently associated with WBCC, whereas 
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CRP did not remain significantly associated in the fully adjusted model 
(Figure 1D). In summary, we demonstrate that autonomic function is 
associated with atherosclerosis and that inflammation could be mediating this 
relationship. The retrospective nature of this study is a limitation, and 
prospective studies are necessary to determine the casual direction between 
these associations.  
4.2 Sympathetic blockade reduces pro-
inflammatory cytokines and 
atherosclerosis in mice (Paper II) 
Increased sympathetic activity is associated with cardiovascular disease 
(138). Some of the risk factors for cardiovascular mortality, such as 
hypertension, can be controlled by the inhibition of sympathetic activity 
using β-blockers. The use of β-blockade is also suggested to have a direct 
effect on the development of atherosclerosis, however the underlying 
mechanisms are still not fully understood. In Paper II, we investigated the 
effects of treatment with the β1-adrenoceptor antagonist, metoprolol, on high 
fat diet-induced atherosclerosis in ApoE-/- mice. These mice were grouped 
under normal conditions, in the absence of generated stress conditions.  
11 weeks of treatment with metoprolol significantly reduced atherosclerosis 
in the thoracic aorta, compared to controls (Figure 2A). In the aortic root, a 
similar effect was discovered, however this did not reach the level of 
significance (Figure 2B). Histology of the aortic root revealed a lower 
composition of macrophage content in the lesions after metoprolol treatment, 
compared to controls (Figure 2E, Paper II). Further, metoprolol reduced the 
serum levels of the pro-inflammatory cytokines TNFα and CXCL1 (Table 1, 
Paper II), and had no effects on total cholesterol in serum (control 12.3 ± 0.5 
versus metoprolol 11.6 ± 0.4 mmol/L).  
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Figure 2. Metoprolol reduced atherosclerosis in ApoE-/- mice. The effect of 8 weeks of 
sympathetic inhibition with the ?1-antagonist metoprolol, on atherosclerosis in the thoracic 
aorta (A), and in the aortic root (B), compared to controls. Data expressed as mean ± SEM 
*P<0.05 
Our data on reduced atherosclerosis from ?-blockade supports previous 
studies in comparable models, showing an athero-protective effect of 
metoprolol (139). Numerous factors could contribute to the beneficial effects 
of the treatment. We did not find any influence on serum total cholesterol 
levels, indicating other mechanisms for the athero-protective effects. We did 
not differentiate between different lipoproteins, thus alterations in the lipid 
profile could be present. In addition, metoprolol reduced the serum levels of 
pro-inflammatory cytokines ?????and CXCL1. These cytokines are involved 
in the pathogenesis of atherosclerosis and attenuation of their presence could 
play a role in inhibiting the disease.  
The chemokine CXCL1 corresponds to growth-regulated oncogene-??
?????????????????????????involved in chemotaxis of leukocytes. CXCL1 and 
its receptor CXCR2 are both present in atherosclerotic lesions, where they 
have an important role in the adhesion of monocytes and accumulation of 
macrophages (140-142). Interestingly, we previously showed that 
sympathetic activation by psychosocial stress increased the plasma levels of 
CXCR1 and increased atherosclerosis (31). ????? contributes to 
atherogenesis in numerous ways, including the induction of vascular cell 
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adhesion molecules VCAM-1 and ICAM-1, and reactive oxygen species 
(143). Importantly, inhibition of TNFα reduced atherosclerosis in ApoE-/- 
mice (144, 145) Adhesion molecules are involved in the recruitment of 
monocytes into the vessel wall, and are commonly upregulated in 
atherosclerosis-prone areas (146). On the notion that TNFα and CXCL1 can 
be involved in the vascular recruitment of monocytes, reduced cytokine 
levels after metoprolol treatment could explain the lower frequency of 
macrophage content in the lesions of the aortic root. In the initiation and 
progression of atherosclerosis, the infiltration of monocytes and their 
subsequent differentiation into accumulating macrophages are essential 
(147). We can only speculate as to why β-blockade reduces pro-inflammatory 
cytokines. One possible explanation could be modulation of ANS. Studies 
have reported that metoprolol treatment both reduces sympathetic activity 
and increases parasympathetic activity (148-150). Interestingly, vagal 
stimulation has been associated with reduced production of TNFα in 
endotoxemic rats (69), a pathway known as the cholinergic anti-inflammatory 
pathway.  
Other athero-protective mechanisms could be present in this study. 
Hypertension is one of the major risk factors for atherosclerosis, and is 
commonly treated with β-blockers. On the other hand, lowering of blood 
pressure seems to have little impact on atherosclerosis in normotensive mice 
(151). Unfortunately, this study cannot provide any data on this subject. 
Importantly, another study using a similar dose of metoprolol showed that 
treatment did not cause any changes in blood pressure (139). In conclusion, 
metoprolol reduces atherosclerosis in ApoE-/- mice, possibly by reducing pro-
inflammatory cytokines. Further, the impact on cytokine production could 
potentially be mediated via reduced sympathetic or increased 
parasympathetic activity.        
4.3 The role of α7nAChR in atherosclerosis 
(Paper III and IV) 
Intrigued by the findings in Paper I and II, displaying a relationship between 
modulation of ANS, inflammation and atherosclerosis, Paper III and IV aim 
to investigate the role of the α7nAChR in atherogenesis. α7nAChR has been 
implicated as a key component in the cholinergic anti-inflammatory pathway, 
where activation of the receptor has been associated with improved outcome 
in a number of different inflammatory experimental models (84-87). 
However, the role of α7nAChR in atherosclerosis has been poorly 
investigated. 
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4.3.1 α7nAChR in mice 
The role of α7nAChR on atherosclerosis in mice was approached using two 
different models. In Paper III, we investigated the atherogenic response in 
absence of hematopoietic α7nAChR in LDLr-/- mice, whereas the main focus 
in Paper IV was the potential effects on atherosclerosis in response to 
pharmacological stimulation of α7nAChR by treatment with the selective 
agonist AZ6983 for 8 or 12 weeks.  
Development of atherosclerosis 
In Paper II, mice reconstituted with bone marrow from α7nAChR-/- mice 
displayed a 74% increase in atherosclerosis, in the aortic root, compared to 
recipients of wild type bone marrow, after 8 weeks on a cholesterol-rich diet 
(Figure 3).  
Figure 3. The role of the α7nAChR in the development of atherosclerosis. Atherosclerosis in 
the aortic root after reconstitution with bone marrow from α7nAChR-/- mice (left), after 
α7nAChR-stimulation with the selective agonist AZ6983 for 8 weeks (middle), or in the 
thoracic aorta after AZ6983-treatment for 12 weeks (right), compared to control mice.  Data 
expressed as mean ± SEM. *P<0.05, **P<0.01, ***P<0.001. 
This was the first study presenting data on the implication of α7nAChR in 
atherosclerosis. Surprisingly, in a following study by Kooijman el al., also 
using the bone marrow transplantation approach, atherosclerosis did not 
differ between the groups, despite a systemic increase in leukocytes and 
elevated levels of pro-atherogenic cytokines (152). In addition, a recent study 
by Lee at al. reported unchanged lesion size after 8 weeks, and to our 
surprise, opposite effects after 14 weeks (153). We can only speculate on the 
cause of the controversial outcomes on atherogenesis. An obvious difference 
between our study and those by Kooijman et al. and Lee et al. is the use of 
male mice in ours, and female mice in theirs (152, 153). However, any 
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possible gender effect on α7nAChR-functionality in atherosclerosis needs to 
be further investigated.  
The beneficial effects of the α7nAChR in atherosclerosis is supported in 
Paper IV, where we demonstrate that pharmacological activation of the 
α7nAChR using the selective agonist AZ6983 inhibits progression of the 
disease, in two separate studies. Mice treated with AZ6983, exhibited 37% 
less atherosclerosis in the aortic root after 8 weeks (Figure 3), and 49% less 
atherosclerosis in the thoracic aorta after 12 weeks (Figure 3), compared to 
controls. This is in line with a recent study by Hashimoto et al., which 
showed that the selective α7nAChR agonist AR-R17779 suppressed 
atherosclerosis in an angiotensin II-induced disease model (154). Hashimoto 
et al. proposed that the anti-atherogenic effects of AR-R17779 could possibly 
be derived from reduced blood pressure or attenuated serum lipid levels 
(154). In addition, expression of mRNA for IL-1β, IL-6 and NADPH oxidase 
2 were decreased in the aortas of treated mice, suggesting a possible impact 
on local inflammation (154). In both our studies, 4 weeks of treatment with 
AZ6983 did not affect serum total cholesterol. At 8 weeks cholesterol was 
affected in opposite directions, and at 12 weeks no differences were detected 
between the groups (Table 1, Paper IV). Thus, changes in total cholesterol 
cannot account for the atherogenic effects of AZ6983, suggesting other 
mechanisms are involved. We did not perform blood pressure measurement 
and cannot rule out any possible anti-hypertensive effects of the drug on 
atherosclerosis.  
Immune cells and inflammatory responses 
Analysis of aortic mRNA in Paper III showed that α7nAChR-/- transplanted 
mice exhibited increased IFNγ mRNA (Figure 2C, Paper III). IFNγ is 
produced by T-cells and are involved in a number of pro-atherogenic immune 
responses (155). This could possibly indicate that aggravated local 
inflammation in the vessels may contribute to the increase in atherosclerosis. 
Since the spleen has been implicated as an important organ in the cholinergic 
anti-inflammatory pathway (156), splenic mRNA was analyzed with RT-
qPCR. To our surprise, α7nAChR-/- transplanted mice displayed increased 
FoxP3 mRNA in the spleen (Supplemental Figure 2A, Paper III), compared 
to controls. FoxP3 is expressed by regulatory T-cells that are regarded as 
anti-inflammatory. However, there are reports on the presence of FoxP3+ T-
cells with pro-inflammatory properties, in the spleen, atherosclerotic aortas 
and mesenteric lymph nodes (157). Importantly, in a separate experiment 
where splenocyte subsets were compared between α7nAChR-/- and WT mice, 
flow cytometry did not detect any differences in the frequency of FoxP3+ 
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cells between the groups (data not shown). Thus, the functional relevance of 
increased splenic FoxP3 mRNA in the BMT-study should be interpreted with 
caution. Interestingly, Kooijman et al. also reported increased systemic 
immune-activity in α7nAChR-/- transplanted mice, including increased 
numbers of leukocytes in multiple compartments, elevated CRP and TNFα 
mRNA in peritoneal cells, as well as increased TNFα in the spleen, compared 
to controls (152). Taken together, these studies suggest aggravated pro-
inflammatory activity of the immune system in absence of hematopoietic 
α7nAChR. Further, these immune responses might be present both 
systemically and locally in the vessels.  
In Paper III, the immune-regulating role of α7nAChR in lymphoid organs 
was only investigated briefly. Thus, in Paper IV we addressed this subject 
more thoroughly. Treatment with the selective α7nAChR agonist AZ6983 
reduced splenic mRNA of CD86, CD4, CD8 and IFNγ (Table 2). Further, 
AZ6983 reduced the frequency of CD3+ T-cells, whereas CD11b+ monocyte 
frequency was increased (Table 2). Of CD11+ monocytes, AZ6983 treatment 
increased the frequency of Ly6Chigh monocytes and decreased the frequency 
of Ly6Clow monocytes (Table 2). To further investigate the immune 
response in proximity to the aorta, aortic lymph nodes were analyzed with 
RT-qPCR. AZ6983 treatment increased IL-1β mRNA, and reduced CD86 
mRNA, compared to controls. 
Table 2. Lymphoid immune responses after treatment with the α7nAChR-agonist AZ6983 
Selected data on immune related responses in spleen, or aortic lymph nodes, reported in Paper 
IV. Up and down arrows represent significant changes in mRNA or cell population 
frequencies, and their direction, after 8 weeks of treatment with the α7nAChR-agonist 
AZ6983, compared to control mice. na: not assessed, LN: lymph nodes.   
 Marker Spleen Aortic LN 
mRNA levels CD4 ↓ ↔ 
 CD8 ↓ ↔ 
 CD86 ↓ ↓ 
 IL-1β ↔ ↑ 
 IFNγ ↓ ↔ 
Cell populations CD11b+ monocytes ↑ na 
 CD3+ lymphocytes ↓ na 
 CD11b+ Ly6Chigh monocytes ↑ na 
 CD11b+ Ly6Clow monocytes ↓ na 
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Treatment with AZ6983 reduced splenic mRNA for IFNγ, T-cell markers 
CD4 and CD8, and CD86. In addition, flow cytometry showed that AZ6983 
reduced the frequency of CD3+ T-cells. CD86 is expressed by antigen 
presenting cells and is important for T-cell activation (158). Since these 
markers are all related to T-cells, this suggests that AZ6983 suppresses T-cell 
activity in the spleen, an effect that could contribute to the athero-protective 
effects of the treatment. To our surprise, AZ6983 increased the frequency of 
CD11b+ monocytes and skewed the phenotype into a more pro-atherogenic 
Ly6high subpopulation (159). This is in disparity with our finding of reduced 
atherosclerosis. It is hard to find an explanation for this, however cell-
frequencies are in relation to the number of counted cells, and cannot give 
information on whether the total number of Ly6Chigh monocytes is increased 
after treatment. Moreover, it has been suggested that the spleen can have an 
acute reservoir function for monocytes. Myocardial infarction triggers the 
release of monocytes from the spleen into the circulation, reducing the 
numbers in the spleen and increasing the numbers in the blood stream (160). 
It is interesting to further speculate that treatment with AZ6983 could retain 
pro-atherogenic monocytes in the spleen, reducing their presence in the blood 
stream and the subsequent recruitment into the vessels. Unfortunately, we did 
not measure any circulating immune cells and this needs to be further 
investigated.     
In accordance with the spleen, CD86 mRNA in aortic lymph nodes was 
decreased after treatment with AZ6983, suggesting reduced activation of T-
cells. Further, AZ6983 dramatically increased IL-1β mRNA. This finding 
was notable since IL-1β mainly has a pro-inflammatory role in 
atherosclerosis (161-163), even though it has been suggested that IL-1β can 
improve plaque stability (164). This needs to be further investigated. This 
study is limited in describing where the interaction between AZ6983 and the 
α7nAChR occurs. The lymphoid immune responses may indicate a direct or 
indirect interaction with immune cells in lymphoid organs. The expression of 
α7nAChR on splenic macrophages has already been reported as a regulator of 
inflammation (77), and there might also be a role for other α7nAChR-
expressing immune cells.  
In summary, this data provides information on an athero-protective role for 
α7nAChR in mice. Hematopoietic α7nAChR deficiency accelerates 
atherosclerosis, whereas stimulation of the receptor with the selective agonist 
AZ6983 attenuates disease progression. Further, α7nAChR presence and 
activation seems closely linked to modulation of both adaptive and innate 
immune responses in the spleen, as well as in closer proximity to aortic 
lesions. We suggest that these immune-modulating effects, at least partly, 
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could be mediating the beneficial effects of α7nAChR-signaling in 
atherosclerosis. However, the exact mechanisms need to be further 
investigated.  
4.3.2 α7nAChR in humans 
Apart from its neuronal expression, the α7nAChR has been identified in a 
number of different human immune cells (74-76). Since we showed an anti-
atherogenic and immune-modulating role for α7nAChR in mice, we wanted 
to investigate if α7nAChR-expressing immune cells are present in human 
atherosclerotic plaques. Further, we wanted to evaluate if circulating immune 
cells respond to α7nAChR-stimulation.  
α7nAChR expression in carotid lesions (Paper II) 
Peroxidase staining revealed that α7nAChR was expressed in inflamed 
regions of human carotid plaques (Figure 4 A). Further, double stainings 
showed that the expression of α7nAChR co-localized with both CD68+ 
(Figure 4 B) and CD163+ macrophages (Figure 4 C), and CD3+ T-cells 
(Figure 4 D). The expression of α7nAChR on CD163+ macrophages was 
confirmed with analysis of mRNA patterns from the global gene expression 
array database of BIKE. mRNA for Chrna7, the coding gene for α7nAChR, 
and CD163 were significantly correlated (r=0.282, P=0.0033).  
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Figure 4.  ???? ??????????? ??? ???????? ??? ?????? ???????????????? ???????. Representative 
immunoperoxidase staining of the ???????? ??? ?????? ???????? ??????s (A). 
Immunofluorescent double stainings showing co-????????????????????????????????????????D), 
with macrophage markers CD68 (B) and CD163 (C), and T-cell marker CD3 (D), in red. 
Nuclei are stained in blue with 4’,6-diamidino-2-phenylindole.  
This suggests that human atherosclerotic plaques con????? ???????-
??????????? ??????? ??????? ??? ?????? ???????? ?????? ???????+ immune cells 
comprise T-?????? ???? ????????????? ?????? ??????? co-localized with 
CD163, a marker for M2 polarized macrophages, we speculate that the 
receptor is expressed by this subset, known to exhibit anti-inflammatory 
properties (165, 166). We find this interesting, since it indicates that 
treatment with ???????-agonists may promote local interaction with 
immune cells in the vessels, and needs to be further investigated.  
??????? activation by AZ6983 attenuates cytokine response 
in human blood  
AZ6983 attenuated the response of pro-inflammatory cytokines TNF???IL-???
and IL-6 in LPS-challenged blood from healthy donors (Figure 5). The 
inhibitory effects were significant at AZ6983 concentrations of 10 and 100 
μmol/L for TNF?? and 100 μmol/L for IL-?????????-6 (Figure 5). 
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Figure 5. AZ6983 inhibits pro-inflammatory cytokine production in human blood ex vivo. The 
production of pro-inflammatory cytokines TNFα, IL-1β and IL-6 in lipopolysaccharide (10 
ng/ml) challenged blood from healthy subject in presence of PBS or 0.1, 1, 10 or 100 μmol/L 
of the α7nAChR agonist AZ6983. Bars represent % response of LPS stimulations and are 
expressed as mean ± SEM. PBS: Phosphate-buffered saline, LPS: Lipopolysaccharide. 
*P<0.05, **P<0.01, ***P<0.001.  
Here we show that AZ6983 effectively reduces production of pro-
inflammatory cytokines in LPS-challenged human blood. The effect of 
AZ6983 is similar to previous studies on the selective α7nAChR agonist 
GTS-2 and the broad cholinergic agonist nicotine, where treatment reduced 
pro-inflammatory cytokines in comparable models (167, 168). Compared to 
GTS-21 and nicotine, the suppressive effects of AZ6983 are present at lower 
concentrations, suggesting AZ6983 to be more potent (167, 168). Since 
TNFα, IL-1β and IL-6 all are associated with the pathophysiology of 
atherosclerosis (16), this could indicate that AZ6983 also might have a potent 
effect on inhibiting lesion development in humans.  
 35 
C
yt
ok
in
es
 in
 h
um
an
 b
lo
od
(%
 o
f L
P
S
 re
sp
on
se
)
IL-6
0
50
100
150
200
** ***
***
***
LPS + AZ6983 (0.1 µmol/L) 
LPS + PBS 
LPS + AZ6983 (1 µmol/L)
LPS + AZ6983 (10 µmol/L)
LPS + AZ6983 (100 µmol/L) 
AZ6983 (100 µmol/L)
IL-1β TNFα
The Role of the Autonomic Nervous System in Atherosclerosis 
5 SUMMARY AND CONCLUSION 
In this thesis, we investigated the link between the ANS, inflammation 
and atherosclerosis. We show that there is an association between autonomic 
dysfunction, measured by BRS, and carotid atherosclerosis in men. However, 
this association was attenuated when adjusting for the inflammatory marker 
WBCC. Thus, it appears that inflammation could be mediating this 
relationship. This was further supported by our novel demonstration of an 
independent association between autonomic dysfunction and WBCC, and 
between WBCC and carotid atherosclerosis. Since BRS is regarded as a 
parasympathetic marker, dysfunction in this branch of the ANS may be of 
relevance for disease progression.  
We also found evidence of a link between sympathovagal balance, 
inflammation and disease progression by suppressing sympathetic activity in 
hypercholesterolemic mice. Treatment with the β1-adrenoceptor antagonist, 
metoprolol, attenuated atherosclerosis and reduced serum levels of the pro-
inflammatory cytokines TNFα and CXCL1. Since these cytokines play a part 
in the pathophysiology of atherosclerosis, suppressed inflammation in 
response to reduced sympathetic drive or increased parasympathetic activity, 
may contribute to the athero-protective effects. While the sympathetic 
nervous system has gained a lot of attention in the cardiovascular field, the 
parasympathetic nervous system has been demonstrated to have an immune-
modulating role in other fields. Others have shown that vagal stimulation 
reduces pro-inflammatory cytokines via activation of the α7nAChR, 
improving outcomes in experimental models of other inflammatory diseases. 
This prompted us to investigate the role of α7nAChR in atherosclerosis.  
For the first time, we reveal an athero-protective role for the α7nAChR. 
α7nAChR-deficiency increased IFNγ mRNA in aorta and accelerated 
atherosclerosis, whereas stimulation with the novel agonist AZ6983 
modulated immune responses in lymphoid organs, and attenuated 
atherosclerosis. Further, the α7nAChR was identified on T-cells and 
macrophages in human carotid plaques, and stimulation of α7nAChR in 
human blood effectively inhibited production of pro-inflammatory cytokines.  
Taken together, our findings suggest that the balance between the two 
branches of ANS could have an impact on atherosclerosis, and that 
inflammation may mediate this response. Although underlying mechanisms 
are elusive, signaling via the α7nAChR could be part of this pathway. 
Pharmacological targeting of the α7nAChR using AZ6983 could be a future 
intervention for atherosclerosis, and should be further investigated.     
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